Launch of Whole Genome Supercomputer

October 2012

A GREAT LEAP FORWARD IN CANCER TREATMENT: Launch of Next Generation Genomic Supercomputing Platform Reduces Cancer Treatment Analysis from Months to Seconds

THIS CIRCOS PLOT VISUALIZES DATA FROM THE CANCER GENOME ATLAS (TCGA) AND ALLOWS SCIENTISTS TO EXPLORE THE INTERRELATIONSHIPS AMONG DIFFERENT DATA POINTS. (IMAGE COURTESY OF CANCER.GOV)

THIS CIRCOS PLOT VISUALIZES DATA FROM THE CANCER GENOME ATLAS (TCGA) AND ALLOWS SCIENTISTS TO EXPLORE THE INTERRELATIONSHIPS AMONG DIFFERENT DATA POINTS. (IMAGE COURTESY OF CANCER.GOV)

At an event hosted by the Bipartisan Policy Center (BPC) and Doctors Helping Doctors, alongside Senator Bill Frist, MD, Senior Fellow at the BPC, J. Michael McGinnis, MD, Senior Scholar at the Institute of Medicine, medical thought leaders, philanthropists, and representatives from leading global businesses, Dr. Patrick Soon-Shiong, Chairman of NantHealth and the Chan Soon-Shiong Institute for Advanced Health, will announce a revolutionary advance in cancer treatment innovation on October 3rd at 8:00am ET at the Newseum in Washington, D.C.

For the full report, click here.


Launch of the Nation’s Fastest Genomic Supercomputing Platform Reduces Cancer Genome Analysis from Months to Seconds -- One Patient Every 47 Seconds

Bringing genomic medicine into clinical practice by placing supercomputers in the hands of physicians at point of care

Alongside Senator Bill Frist, MD, of the Bipartisan Policy Center and J. Michael McGinnis, MD of the Institute of Medicine and Doctors Helping Doctors, Dr. Soon-Shiong reported on the successful real-time analysis of the largest collection of tumor genomes in the United States, of 6,017 cancer genomes from 3,022 patients with 19 different cancer types, in the record time of 69 hours. Genomic analysis has taken an average of 8 to 10 weeks to complete. That delay leads not just to less efficient, more costly care, but sometimes to the wrong course of treatment altogether – and, thus, higher mortality. “Incorrect care that leads to loss of life is unacceptable,” said Dr. Soon-Shiong, “and from today onward, it will no longer be necessary.”

Dr. Patrick Soon-Shiong, Chairman of NantHealth and the Chan Soon-Shiong Institute for Advanced Health announced a revolutionary advance in cancer treatment that will reduce the necessary time for analysis from 8 weeks to an unprecedented 47 seconds per patient. For the first time, oncologists can compare virtually every known treatment option on the basis of genetics, risk, and cost – before treatment begins, not after.

For the full report, click here.


Quantitative Proteomics in the Clinical Setting: OncoPlex Diagnostics Receives Accreditation Certification from the College of American Pathologists

October 22, 2013

OncoPlex Diagnostics has received certification of accreditation from the College of American Pathologists (CAP) following inspection of the clinical laboratory facility in Rockville, MD. OncoPlexDx laboratory is the only service that uses mass spectrometry to provide oncologists with precise quantitative measurement of multiple oncoproteins from tissue leading to better treatment decisions.

Dr. Patrick Soon-Shiong describes what is proteomics and its role in finding a cure for cancer.

CAP accreditation is the gold standard awarded to clinical laboratories that exceed inspection qualifications. OncoPlexDx is now both CAP-accredited and CLIA-certified for clinical sample processing of Formalin-Fixed, Paraffin-Embedded (FFPE) cancer tissue using Selected Reaction Monitoring Mass Spectrometry. "Achieving the CAP accreditation combined with our CLIA certification demonstrates unwavering commitment to excellence at OncoPlex Diagnostics," says Jon Burrows, CEO. "Clinicians ordering our assays can have confidence that the results received are of the highest quality possible."


Dr. Patrick Soon-Shiong Keynotes at NHS Confederation Annual Conference and Exhibition

June 2014

Dr. Patrick Soon-Shiong speaking at the 2014 NHS Confederation annual conference and exhibition.

Genomics England and University of Oxford

October 2014

Chan Soon-Shiong Institute for Molecular Medicine and the University of Oxford Establish Partnership to Create the First Center for Genomic and Proteomic Medicine in the United Kingdom to Benefit NHS Cancer Patients as Part of a $50M Commitment

The Chan-Soon-Shiong Oxford Center for Molecular Medicine Will Advance Cancer Care with Individualized Information at the Molecular Level and State-of-the-Art Proteomic Technology

“This partnership will evaluate and provide comprehensive molecular diagnostics from genomics to proteomics integrated with clinical data for cancer patients with the aim to identify the right treatment for the right patient at the right time.” — Anna Schuh, University of Oxford
“This partnership will evaluate and provide comprehensive molecular diagnostics from genomics to proteomics integrated with clinical data for cancer patients with the aim to identify the right treatment for the right patient at the right time.”

— Anna Schuh, University of Oxford

October 23, 2014 -  Pharma Discussion

The Chan Soon-Shiong Institute for Molecular Medicine (CSSIOMM) and the University of Oxford announced a partnership to establish the Chan Soon-Shiong Oxford Center for Molecular Medicine (CSSOCMM), the first of its kind in the United Kingdom designed to support the delivery of individualized, data-driven molecular based medicine for the benefit of NHS cancer patients. The Chan Soon-Shiong Institute has made an initial commitment of $50M to advance clinical cancer care in the UK through genomic and proteomic driven diagnoses. These funds will provide doctors with large-scale sequencing capabilities for patient-level genomic, epigenomic, proteomic, and digital pathology data capture as well as novel tools and supercomputing technology to support critical decision making for cancer treatment. 

Today’s announcement is being made at a press conference in London at which the Minister for Life Sciences, George Freeman MP will preside. Commenting on the announcement, he said: “This investment is a sign that Britain is leading the world in the exciting new field of Genomic Medicine. Breakthroughs in our understanding of how genetics determines how disease really works in patients is crucial to generating new treatments and medicines.


60 Minutes: DISRUPTING CANCER…Dr. Soon-Shiong, Turning Heads With More Unconventional Ways Of Treating The Disease He Hopes To Conquer

December 2014

Dr. Patrick Soon-Shiong has already struck a blow against cancer, inventing a drug to fight the disease that's helped to make him the richest man in Los Angeles. Now the surgeon and entrepreneur is using nearly a billion dollars of his fortune to go full throttle into an unconventional method of fighting cancer that he hopes will make it a chronic, treatable disease instead of a death sentence. Dr. Sanjay Gupta reports on Soon-Shiong and his cancer research for a 60 Minutes story to be broadcast on Sunday, Dec. 7.

DECEMBER 7, 2014 - DR. SANJAY GUPTA REPORTS ON SOON-SHIONG AND HIS CANCER RESEARCH FOR A 60 MINUTES STORY.

DECEMBER 7, 2014, - Patrick Soon-Shiong: An owner of the L.A. Lakers, friend of Kobe Bryant, and a doctor who's shaking up the world of cancer.

Most cancer treatment is governed by the location of the tumor; some drugs are for breast cancer, others work better against lung cancer, for example. Soon-Shiong has built an infrastructure to enable his researchers to map the entire genome of individual tumors, a process that once could have taken months but with new supercomputers can be done in a day. The idea is to learn as much about a tumor's mutations so the bad mutations can be identified. It's thought that by classifying the cancer by its mutations, each bad mutation can be seen as a separate disease to treat individually with specifically designed drugs.

"Imagine reclassifying cancer...and understand that cancer's a slew of rare diseases," says Soon-Shiong. "It's going to mean you have a better shot at having a better outcome and having a quality of life and actually turn the cancer, hopefully, into a chronic disease," he tells Gupta.

DIANE'S STORY ABOUT HER BATTLE WITH PANCREATIC CANCER. SHE HAS BEEN IN A REMISSION FOR OVER A YEAR AFTER TREATMENT WITH ABRAXANE.

LEARN HOW DAVID BATTLED THROUGH HIS UNIQUE FORM OF CANCER TO HELP THE BREAKTHROUGHS ADVANCE.


Cancer Breakthroughs 2020: GPS Cancer Insurance Reimbursement

February 2016